The trademark application e was filed by E-THERAPEUTICS PLC, a corporation established under the laws of the United Kingdom of Great Britain and Northern Ireland (the "Applicant"). The application was published for oppositions on September 4, 2022, and it was registered by office on December 12, 2022 without any oppositions.
The application was filed in English (German was selected as the second language).
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical and medical preparations
Pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression
RNAi-based medicines and pharmaceuticals
Short interfering RNA (siRNA) medicines and pharmaceuticals
Nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression
Pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation.
The mark was filed in class 9 with following description of goods:
Computer software
Downloadable computer software
Computer software for use in the field of pharmaceuticals, medicines and drug discovery
Artificial intelligence and machine learning software
Artificial intelligence and machine learning software for use in the field of pharmaceuticals, medicines and drug discovery
Databases
Electronic databases for use in the field of pharmaceuticals, medicines and drug discovery
Computer platform software
Computer software platforms
Computer platform software for use in the field of pharmaceuticals, medicines and drug discovery
Computer software platforms for use in the field of pharmaceuticals, medicines and drug discovery.
The mark was filed in class 40 with following description of goods:
Custom manufacture of pharmaceutical and medical preparations
Custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression
Custom manufacture of RNAi-based pharmaceuticals and medicines
Custom manufacture of short interfering RNA (siRNA) medicines
Custom manufacture of nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression
Custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation
Provision of information, advice and consultancy services relating to all of the aforesaid.
The mark was filed in class 42 with following description of goods:
Scientific research and development
Pharmaceutical research and development services
Scientific research and development in the field of targeting genes and blocking, silencing or inhibiting gene expression
Scientific, pharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines
Scientific, pharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression
Scientific, pharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking gene expression, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and, pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation
Drug discovery services
Drug discovery services relating to RNAi-based pharmaceuticals and medicines
Drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression
Drug discovery services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation
Genetic research
Scientific and technical data analysis
Scientific and technical data analysis in relation to pharmaceuticals and medicines
Scientific and technical data analysis in relation to RNAi-based medicines
Scientific and technical data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression
Scientific and technical data analysis in relation to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation
Design, development, creation and maintenance of computer platforms and computer software
Design, development, creation and maintenance of computational platforms
Design, development, creation and maintenance of computer platforms and computer software for use in the field of pharmaceuticals, medicines and drug discovery
Platform as a Service (PaaS)
Platform as a Service (PaaS) services relating to the use of artificial intelligence and machine learning software and databases in the field of pharmaceuticals, medicines and drug discovery
Platform as a Service (PaaS) services relating to the use of artificial intelligence and machine learning software and databases in relation to RNAi-based medicines and pharmaceuticals, short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation
Design and development of computer-simulated models
Design of computer-simulated models for use in the field of pharmaceuticals, medicines and drug discovery
Providing non-downloadable computer software
Providing non-downloadable computer software for use in the field of pharmaceuticals, medicines and drug discovery
Software as a Service (SaaS)
Software as a Service (SaaS) services relating to the use of artificial intelligence and machine learning software and databases in the field of pharmaceuticals, medicines and drug discovery
Software as a Service (SaaS) services relating to the use of artificial intelligence and machine learning in relation to RNAi-based medicines and pharmaceuticals, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation
Provision of information, advice and consultancy services relating to all of the aforesaid.